parallel randomized trial

S002963

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Other conditionsS002963

Design

Randomized
Start year
Treatment: 6 weeks, follow-up 6 weeks
Countries
Sponsor: (not reported)
Eligibility: major depressive disorder, BMI 27 or more, HDRS above 20

Conduct and analysis

Blinding: double blind
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized	Analyzed	Completed treatment
A1	Liraglutide 3.0 mg subcutaneous once daily Liraglutide 3.0 mg plus escitalopram	escitalopram 20 mg once daily; lifestyle: not reported
A2	Placebo Placebo plus escitalopram	escitalopram 20 mg once daily; lifestyle: not reported

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.

Characteristic	Statistic	Whole trial ALL
age	mean (years)	41.2
bmi	mean (kg/m2)	33.9
female	percent	60